SAN FRANCISCO, Nov. 20 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging company in complement depletion, announced that it has appointed Kevin L. Stark, Ph.D. as President and Chief Executive Officer, effective immediately. Dr. Stark has more than 19 years experience as a biopharmaceutical researcher and executive, most recently as an Executive Director at Amgen, and Chief Operating Officer at iZumi Bio, Inc. His latest responsibilities included strategic operations within R&D, integration of mergers and acquisitions, licensing, and business development.
"We are very pleased to appoint Kevin Stark as our CEO," said Jay Lichter, Ph.D., Chairman of the Board. "We believe his experience, which spans basic research to executive management, will be instrumental as the company advances into drug development and seeks potential partnerships."
Dr. Stark received a Ph.D. in Pharmacology from the
InCode also announced that William St. John has resigned as President and Chief Executive Officer, and will remain on the Board of Directors.
"We are very grateful to Bill for his vision in recognizing the promise of complement depletion in human disease, and his role in building the company to this point," said Carl-Wilhelm Vogel, MD, Ph.D., Founder and Board Member, from the Cancer Research Center of Hawaii.
In conjunction with this transition, the company will shift operations from the San Francisco, CA location to the Thousand Oaks, CA area.
InCode's novel approach is focused on the selective interruption of the
complement cascade. Activation of the complement cascade has been implicated
in the pathogenesis of many inflammatory diseases, including rheumatoid
arthritis, asthma, ischemia-reperfusion injury and age-related macular
|SOURCE InCode BioPharmaceutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved